Cogent Biosciences (COGT) Net Income towards Common Stockholders (2017 - 2026)

Cogent Biosciences' Net Income towards Common Stockholders history runs 10 years deep, the most recent figure standing at -$97.2 million for Q1 2026.

• In Q1 2026, Net Income towards Common Stockholders fell 35.05% year-over-year to -$97.2 million; the TTM figure through Mar 2026 stood at -$347.0 million (down 27.8% YoY), while the FY2025 annual figure was -$321.7 million, down 24.78% from the prior year.
• Net Income towards Common Stockholders was -$97.2 million for Q1 2026 at Cogent Biosciences, down from -$95.3 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of -$31.3 million in Q1 2022 to a low of -$97.2 million in Q1 2026.
• Historically, Net Income towards Common Stockholders has averaged -$59.7 million across 5 years, with a median of -$58.3 million in 2024.
• The sharpest annual moves came in 2022 and 2025: Net Income towards Common Stockholders plunged 147.03% in 2022, then dropped 14.57% in 2025.
• A 5-year view of Net Income towards Common Stockholders shows it stood at -$41.6 million in 2022, then sank by 30.56% to -$54.4 million in 2023, then slipped by 28.55% to -$69.9 million in 2024, then tumbled by 36.39% to -$95.3 million in 2025, then slipped by 2.0% to -$97.2 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$97.2 million (Q1 2026), -$95.3 million (Q4 2025), and -$80.9 million (Q3 2025), per Business Quant data.